|
CA2019714A1
(en)
|
1989-06-27 |
1990-12-27 |
Richard A. Chizzonite |
Process for the determination of interleukins
|
|
DZ2788A1
(fr)
|
1998-05-15 |
2003-12-01 |
Bayer Ag |
Agonistes et antagonistes selectifs à IL-2.
|
|
EP1105421A2
(en)
|
1998-08-21 |
2001-06-13 |
Yeda Research & Development Company, Ltd. |
Anti-inflammatory peptides derived from il-2 and analogues thereof
|
|
JP5179689B2
(ja)
|
2000-02-11 |
2013-04-10 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
抗体ベース融合タンパク質の循環系内半減期の増強
|
|
US6689353B1
(en)
|
2000-06-28 |
2004-02-10 |
Bayer Pharmaceuticals Corporation |
Stabilized interleukin 2
|
|
CZ2003214A3
(cs)
|
2000-06-29 |
2003-08-13 |
Merck Patent Gmbh |
Zesílení odpovědi mediovaných fúzním proteinem protilátka-cytokin kombinovanou léčbou pomocí činidel zvyšujících uptake imunocytokinu
|
|
EP1454138B1
(en)
|
2001-12-04 |
2012-01-18 |
Merck Patent GmbH |
Immunocytokines with modulated selectivity
|
|
WO2005007121A2
(en)
|
2003-07-18 |
2005-01-27 |
Massachusetts Institute Of Technology |
Mutant interleukin-2(il-2) polypeptides
|
|
US8147832B2
(en)
|
2003-08-14 |
2012-04-03 |
Merck Patent Gmbh |
CD20-binding polypeptide compositions and methods
|
|
AU2013205042B2
(en)
*
|
2004-12-22 |
2016-05-12 |
Ambrx, Inc. |
Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
|
|
ES2432141T3
(es)
|
2005-01-27 |
2013-11-29 |
Novartis Vaccines And Diagnostics, Inc. |
Procedimientos para tratar carcinoma de células renales
|
|
US7667076B2
(en)
|
2005-09-14 |
2010-02-23 |
Regents Of The University Of California |
Amide forming chemical ligation
|
|
WO2009061853A2
(en)
|
2007-11-05 |
2009-05-14 |
Massachusetts Institute Of Technology |
Mutant interleukin-2 (il-2) polypeptides
|
|
WO2010085495A1
(en)
|
2009-01-21 |
2010-07-29 |
Amgen Inc. |
Compositions and methods of treating inflammatory and autoimmune diseases
|
|
ES2866674T3
(es)
|
2010-11-12 |
2021-10-19 |
Nektar Therapeutics |
Conjugados de una fracción de IL-2 y un polímero
|
|
CU23923B1
(es)
|
2010-11-12 |
2013-07-31 |
Ct De Inmunología Molecular |
Polipéptidos derivados de la il-2 con actividad agonista
|
|
WO2012088446A1
(en)
|
2010-12-22 |
2012-06-28 |
Board Of Trustees Of The Leland Stanford Junior University |
Superagonists and antagonists of interleukin-2
|
|
CN105440123B
(zh)
|
2011-02-10 |
2020-10-09 |
罗切格利卡特公司 |
突变体白介素-2多肽
|
|
US11492383B2
(en)
|
2011-06-24 |
2022-11-08 |
Stephen D. Gillies |
Light chain immunoglobulin fusion proteins and methods of use thereof
|
|
US9844582B2
(en)
|
2012-05-22 |
2017-12-19 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
|
|
EP3004062B1
(en)
|
2013-05-24 |
2017-07-19 |
SynAffix B.V. |
Substituted azadibenzocyclooctyne compounds and their use in metal-free click reactions
|
|
EP3097080A1
(en)
|
2014-01-24 |
2016-11-30 |
SynAffix B.V. |
Process for the cycloaddition of a halogenated 1,3-dipole compound with a (hetero)cycloalkyne
|
|
PT3102595T
(pt)
|
2014-02-06 |
2019-01-11 |
Hoffmann La Roche |
Proteínas de fusão de interleucina-2 e suas utilizações
|
|
PT3134123T
(pt)
|
2014-02-21 |
2021-03-22 |
Nektar Therapeutics India Pvt Ltd |
Agonistas seletivos de il-2rbeta em combinação com um anticorpo anti-ctla-4 ou um anticorpo anti-pd-1
|
|
JP6592505B2
(ja)
|
2014-04-24 |
2019-10-16 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
インターロイキン−2のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト
|
|
JP6640834B2
(ja)
|
2014-08-11 |
2020-02-05 |
デリニア, インコーポレイテッド |
自己免疫疾患の処置のために調節性t細胞を選択的に活性化させる改変il−2変異体
|
|
EP3180018B1
(en)
|
2014-08-12 |
2019-07-24 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
|
|
WO2016025647A1
(en)
|
2014-08-12 |
2016-02-18 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
|
|
ES2774380T3
(es)
|
2014-08-29 |
2020-07-20 |
Hoffmann La Roche |
Politerapia de inmunocitocinas de variante de IL-2 dirigida a tumor y anticuerpos frente a PD-L1 humano
|
|
JP7299021B2
(ja)
|
2015-09-11 |
2023-06-27 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
生体関連の直交性サイトカイン/受容体ペア
|
|
US20170204154A1
(en)
|
2016-01-20 |
2017-07-20 |
Delinia, Inc. |
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
WO2017139570A1
(en)
|
2016-02-12 |
2017-08-17 |
Massachusetts Intitute Of Technology |
Synergistic tumor treatment with il-2, an integrin-binding-fc fusion protein, and a cancer vaccinne
|
|
US10898576B2
(en)
|
2016-03-16 |
2021-01-26 |
Yanhui Xie |
Glucocorticoid combined with polyethylene glycol-modified interleukin 2 for treating respiratory disease
|
|
KR20240115933A
(ko)
|
2016-05-04 |
2024-07-26 |
암젠 인크 |
T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
|
|
US11395853B2
(en)
|
2016-06-23 |
2022-07-26 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Biomimetic drug delivery of an immunomodulatory agent for the treatment of ocular conditions
|
|
EP4631529A3
(en)
|
2016-06-28 |
2026-03-11 |
Ventana Medical Systems, Inc. |
Application of click chemistry for signal amplification in ihc and ish assays
|
|
EP3538548A4
(en)
|
2016-11-08 |
2020-08-19 |
Delinia, Inc. |
IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
|
|
CA3043597A1
(en)
|
2016-11-10 |
2018-05-17 |
Nektar Therapeutics |
Immunotherapeutic tumor treatment method
|
|
CU24483B1
(es)
|
2016-11-15 |
2020-04-02 |
Ct Inmunologia Molecular |
Método para incrementar los niveles de secreción de la interleucina-2
|
|
CN110325205B
(zh)
|
2016-12-22 |
2023-08-15 |
库尔生物制药有限公司 |
T细胞调节性多聚体多肽及其使用方法
|
|
JP7005638B2
(ja)
*
|
2017-01-27 |
2022-02-04 |
エヌジーエム バイオファーマシューティカルス,インコーポレーテッド |
グルカゴン受容体結合タンパク質及びその使用方法
|
|
KR102461885B1
(ko)
|
2017-04-03 |
2022-11-03 |
에프. 호프만-라 로슈 아게 |
항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체
|
|
KR20190136076A
(ko)
|
2017-04-13 |
2019-12-09 |
에프. 호프만-라 로슈 아게 |
암 치료 방법에 사용하기 위한 인터루킨-2 면역접합체, cd40 작용제 및 임의적인 pd-1 축 결합 길항제
|
|
AU2018273914A1
(en)
|
2017-05-24 |
2019-11-14 |
Pandion Operations, Inc. |
Targeted immunotolerance
|
|
AU2018287317B2
(en)
|
2017-06-19 |
2024-06-20 |
Medicenna Therapeutics Inc. |
Uses and methods for IL-2 superagonists, agonists, and fusions thereof
|
|
US20190023760A1
(en)
|
2017-07-24 |
2019-01-24 |
Eth Zurich |
Method for preparing interleukin-2 or interleukin-2 analogues
|
|
IL321812A
(en)
|
2017-08-03 |
2025-08-01 |
Synthorx Inc |
Cytokine complexes for the treatment of autoimmune diseases
|
|
US12030940B2
(en)
|
2017-08-17 |
2024-07-09 |
Nektar Therapeutics |
Immunotherapeutic tumor treatment method
|
|
KR102777151B1
(ko)
|
2017-11-21 |
2025-03-05 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
인터루킨-2의 부분 효능제
|
|
EP3720871A4
(en)
|
2017-12-06 |
2021-09-15 |
Pandion Operations, Inc. |
TARGETED IMMUNOTOLERANCE
|
|
JP7765181B2
(ja)
|
2017-12-19 |
2025-11-06 |
ゼンコア インコーポレイテッド |
改変されたil-2 fc融合タンパク質
|
|
US11970537B2
(en)
|
2017-12-26 |
2024-04-30 |
Nanjing GenScript Biotech Co., Ltd. |
Fusion protein dimer using antibody Fc region as backbone and use thereof
|
|
CA3115461A1
(en)
|
2018-03-09 |
2019-09-12 |
AskGene Pharma, Inc. |
Novel cytokine prodrugs
|
|
EP3796940A1
(en)
|
2018-05-21 |
2021-03-31 |
Nektar Therapeutics |
Selective treg stimulator rur20kd-il-2 and related compositions
|
|
AU2019288496B2
(en)
*
|
2018-06-22 |
2024-11-21 |
Cugene Inc. |
Interleukin-2 variants and methods of uses thereof
|
|
KR20210057124A
(ko)
|
2018-09-11 |
2021-05-20 |
암브룩스, 인코포레이티드 |
인터류킨-2 폴리펩타이드 접합체 및 그의 용도
|
|
CA3098930A1
(en)
|
2018-09-21 |
2020-03-26 |
Innovent Biologics (Suzhou) Co., Ltd. |
Novel interleukin-2 and use thereof
|
|
MA54952A
(fr)
|
2019-02-06 |
2022-05-11 |
Synthorx Inc |
Conjugués d'il-2 et méthodes d'utilisation de ceux-ci
|
|
KR20220009380A
(ko)
|
2019-05-17 |
2022-01-24 |
선전 엔듀어링 바이오테크 리미티드 |
표적 면역요법을 위한 절단 가능한 사이토카인이 있는 이중특이적 t-세포 연계체
|
|
WO2020252421A2
(en)
|
2019-06-14 |
2020-12-17 |
Cugene, Inc. |
Novel interleukin-2 variants and bifunctional fusion molecules thereof
|
|
CN114787182A
(zh)
|
2019-08-13 |
2022-07-22 |
艾佩斯瑞生物制药公司 |
工程化的白细胞介素-2受体β激动剂
|
|
AU2020329933A1
(en)
|
2019-08-15 |
2022-03-24 |
Cytimm Therapeutics, Inc. |
Modified interleukin 2 (IL-2) polypeptides, conjugates and uses thereof
|
|
EP4013454A1
(en)
|
2019-08-15 |
2022-06-22 |
Synthorx, Inc. |
Immuno oncology combination therapies with il-2 conjugates
|
|
CN110642934B
(zh)
*
|
2019-09-10 |
2022-08-23 |
中国医学科学院北京协和医院 |
靶向调节t细胞的长效白介素-2及其在治疗自身免疫病中的应用
|
|
WO2021050554A1
(en)
*
|
2019-09-10 |
2021-03-18 |
Synthorx, Inc. |
Il-2 conjugates and methods of use to treat autoimmune diseases
|
|
AU2020403148A1
(en)
|
2019-12-13 |
2022-06-30 |
Cugene Inc. |
Cytokine-based bioactivatable drugs and methods of uses thereof
|
|
KR20220140514A
(ko)
|
2020-01-10 |
2022-10-18 |
브라이트 피크 테라퓨틱스 아게 |
변형된 il-2 폴리펩타이드 및 그의 용도
|
|
KR102986821B1
(ko)
|
2020-04-22 |
2026-07-06 |
머크 샤프 앤드 돔 엘엘씨 |
인터류킨-2 수용체 베타 감마c 이량체에 대해 편향되고 비펩티드성 수용성 중합체에 접합된 인간 인터류킨-2 접합체
|
|
US20230272001A1
(en)
|
2020-05-22 |
2023-08-31 |
Merck Sharp & Dohme Llc |
Novel processes for preparing conjugates of the il-2 protein
|
|
WO2022140797A1
(en)
|
2020-12-23 |
2022-06-30 |
Immunowake Inc. |
Immunocytokines and uses thereof
|
|
JP2024504372A
(ja)
|
2021-01-22 |
2024-01-31 |
エルピス・バイオファーマシューティカルズ |
抗pd-l1モノクローナル抗体及びインターロイキン15(il-15)、インターロイキン15受容体15アルファまたはインターロイキン2との融合タンパク質
|
|
AU2022306788A1
(en)
|
2021-07-09 |
2024-01-04 |
Bright Peak Therapeutics Ag |
Conjugates of checkpoint inhibitors with il-2, and uses thereof
|
|
WO2023281482A1
(en)
|
2021-07-09 |
2023-01-12 |
Bright Peak Therapeutics Ag |
Cd20-targeted il-2 and its uses
|
|
KR20240034221A
(ko)
|
2021-07-09 |
2024-03-13 |
브라이트 피크 테라퓨틱스 아게 |
염증성 질환 및 자가면역 질환의 치료를 위한 변형된 il-2 폴리펩티드
|
|
US20230201364A1
(en)
|
2021-07-09 |
2023-06-29 |
Bright Peak Therapeutics Ag |
Antibody conjugates and manufacture thereof
|
|
AU2022307460A1
(en)
|
2021-07-09 |
2024-01-04 |
Bright Peak Therapeutics Ag |
Checkpoint inhibitors conjugated to il-2, and uses thereof
|
|
WO2023161857A1
(en)
|
2022-02-23 |
2023-08-31 |
Bright Peak Therapeutics Ag |
Bifunctional cytokine compositions
|
|
CN116036243B
(zh)
*
|
2022-04-20 |
2026-03-24 |
北京大学宁波海洋药物研究院 |
受体偏向的peg化il-2变体组合及其应用
|
|
WO2024150175A1
(en)
|
2023-01-11 |
2024-07-18 |
Bright Peak Therapeutics Ag |
Conditionally activated proteins and methods of use
|
|
WO2024150174A1
(en)
|
2023-01-11 |
2024-07-18 |
Bright Peak Therapeutics Ag |
Conditionally activated immunocytokines and methods of use
|